Error loading player: No playable sources found

36753

Session III - Current Understanding of the Product Quality Attributes that Impact Safety and Efficacy of AAV-based Gene Therapy Products

Date
June 6, 2022
This product is not available for individual purchase, but it is available as part of the following products:
Thumbnail for Cell & Gene Therapy Products 2022
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…

Adeno-associated viral (AAV) vector-based gene therapy medicinal products hold curative promise for many disease indications. Although these products have been safely administered to hundreds of patients, recent safety issues have highlighted the need to close gaps in knowledge of product attributes and their potential impacts on safety and efficacy. The characterization and understanding of AAV-based gene therapies are improving, yet there remains much to be understood about the product quality attributes that impact safety and efficacy.  For example, improved understanding of attributes that impact duration of transgene expression, as well as immunogenicity, and removal of impurities such as capsids lacking the desired therapeutic genetic material, is of importance going forward. In September, 2021, the US FDA held an advisory committee meeting to discuss safety issues observed for a range of AAV-based products.  While the AdCom focused on clinical considerations, the aspects of product quality that may result in safety issues were not discussed in depth. In this session, presentations will address potential impacts of AAV gene therapy product quality attributes on safety and efficacy, innovative strategies and approaches for enhancing and optimizing vector performance, and limiting patient exposure to impurities. This will be followed by a discussion about where the industry is today with respect to characterizing AAV-based gene therapies, and where it is headed.  

Related Products

Thumbnail for Accelerate Your Viral Vector Analytics with Automated Tools from Bio-Techne
Accelerate Your Viral Vector Analytics with Automated Tools from Bio-Techne
Modern medicines call for modern technologies. Revolutionary cell and gene therapies offer significant promise to treat life-threatening diseases. Getting therapies to market quickly and efficiently requires accurate testing of critical quality attributes, including accurate viral vector analysis…
Thumbnail for Identity testing by NGS as a means of risk mitigation
Identity testing by NGS as a means of risk mitigation
Imagine that you just completed a manufacturing run for a mission critical gene therapy vector. All of your release testing is underway, and you are days away from releasing your product. Per regulatory guidelines, identity testing is performed to confirm the vector sequence is as expected…
Thumbnail for Session IV - Emerging Technologies
Session IV - Emerging Technologies
In recent years, cell and gene therapies have evolved rapidly into approved products for the treatment of both incurable genetic diseases as well as for the treatment of certain cancers…
Thumbnail for Session II - Managing the Complexity of the CGTP Supply Chain
Session II - Managing the Complexity of the CGTP Supply Chain
Cell, gene, and other novel therapies require carefully designed and well executed logistics solutions for supplying lifesaving medicine to patients…